DNA vaccine encoding CD40 targeted to dendritic cells in situ prevents the development of Heymann nephritis in rats

Ya Wang, Yuan Min Wang, Yiping Wang, Guoping Zheng, Geoff Yu Zhang, Jimmy Jianheng Zhou, Thian Kui Tan, Qi Cao, Min Hu, Debbie Watson, Huiling Wu, Dong Zheng, Changqi Wang, Mireille H. Lahoud, Irina Caminschi, David C. Harris, Stephen I Alexander

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)


The CD40-CD154 costimulatory pathway has been shown to be critical for both T-and B-cell activation in autoimmune disease. Here, we assessed the effects of blocking this pathway using CD40 DNA vaccine enhanced by dendritic cell targeting on the development of active Heymann nephritis, a rat model of human membranous nephropathy. DNA vaccination delivers plasmid DNA encoding the target antigen, either alone or in combination with enhancing elements, to induce both humoral and cellular immune responses. To determine whether CD40 DNA vaccine targeting the encoded CD40 directly to dendritic cells would improve the efficacy of the vaccination against self-protein CD40, we utilized a plasmid encoding a single-chain Fv antibody specific for the dendritic cell-restricted antigen-uptake receptor DEC205 (scDEC), the target gene CD40, and the adjuvant tetanus sequence p30. This vaccine plasmid was compared to a control plasmid without scDEC. Rats vaccinated with scDEC-CD40 had significantly less proteinuria and renal injury than did rats receiving scControl-CD40 and were protected from developing Heymann nephritis. Thus, CD40 DNA vaccination targeted to dendritic cells limits the development of Heymann nephritis. 

Original languageEnglish
Pages (from-to)223-232
Number of pages10
JournalKidney International
Issue number2
Publication statusPublished - Feb 2013
Externally publishedYes


  • active Heymann nephritis (HN)
  • CD40
  • DEC205
  • DNA vaccination

Cite this